CN108279307A - Protection and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma - Google Patents
Protection and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma Download PDFInfo
- Publication number
- CN108279307A CN108279307A CN201810088563.9A CN201810088563A CN108279307A CN 108279307 A CN108279307 A CN 108279307A CN 201810088563 A CN201810088563 A CN 201810088563A CN 108279307 A CN108279307 A CN 108279307A
- Authority
- CN
- China
- Prior art keywords
- serum
- gastrin
- test tube
- stablizing
- blood plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150343—Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Abstract
The invention discloses a kind of heparin tubes for having and protecting and stablizing gastrin-releasing peptide precursor function in serum or blood plasma; including test tube; test tube opening is provided with cap outside seal rubber plug and plastics, the protective agent being formulated by casein, lauryl sodium sulfate and Aprotinin is pre-charged in test tube.Due to being pre-charged with protective agent in heparin tube, the holding time of ProGRP samples is substantially prolonged（Sample can stablize preservation 7 days at 28 DEG C）, on the one hand facilitate clinical operation application, can also carry out repetition measurement when suspecting individual pattern detection results abnormities, reduce the probability of testing result false negative, improve the accuracy and clinical value of the item detection result.
Description
Technical field
The present invention relates to field of medical examination, more particularly, to a kind of protection and stablize gastrin release in serum or blood plasma
The heparin tube of peptide precursor.
Background technology
In recent years, lung cancer has become the first killer of China's malignant tumour cause of the death.Lung cancer is divided into non-small cell lung cancer
（NSCLC）And Small Cell Lung Cancer（SCLC）.Wherein, non-small cell lung cancer accounts for about 85%, and 5 years survival rates are 15%, Small Cell Lung Cancer
Though only accounting for about 15%, survival rate is only 1% within 2 years.70% patients with lung cancer has been Locally Advanced or transfer when making a definite diagnosis, and is lost
Best operative chance.If lung cancer can be diagnosed in early days, 5 years survival rates can be improved to 60% or more.
Tumor markers compared with the imageological examinations means such as traditional CT, nuclear magnetic resonance, not only have it is convenient, fast,
The advantages such as at low cost, it is often more important that can aid in the early diagnosis and discovery of cancer, and the dynamic for passing through tumor markers
Monitoring, can assist the process, therapeutic effect and recurrence for judging disease.
Gastrin-releasing peptide precursor（ProGRP）It is a kind of novel tumor markers for lung cancer early diagnosis.Especially
Be directed to Small Cell Lung Cancer With Selective, ProGRP relatively before neuronspecific enolase（NSE）Advantageously.ProGRP and
The sensibility of NSE detections SCLC is respectively 73% and 60%, and specificity is respectively 98% and 92%, and the NSE that compares diagnoses early stage SCLC
Sensibility only 36.84%, and ProGRP diagnosis early stage SCLC sensibility be 63.16%.In addition, ProGRP is compared with there are one NSE
The advantage of bigger is exactly Sample result not to be influenced by haemolysis.
Currently, ProGRP detection kits on the market all suffer from the unstable problem of sample when detecting ProGRP.
The ProGRP kit specifications of Abbott provide：Serum sample can only preserve 3h at 2-8 DEG C, and plasma sample is at 2-8 DEG C
It can preserve for 24 hours.The ProGRP kit specifications of Kang Naige companies provide：Serum sample can only preserve for 24 hours at 2-8 DEG C.This master
Caused by if ProGRP can be cracked due to the protease in serum.On the one hand the fast degradation of ProGRP samples can cause
On the other hand the false negative of testing result can not carry out subsequent experimental, repetition measurement when such as individual pattern detection results abnormities, this gives
The clinical application of the project brings great inconvenience.
Invention content
In view of the above-mentioned problems, the present invention provides a kind of protection and stablizing gastrin-releasing peptide precursor in serum or blood plasma
（ProGRP）Heparin tube；The heparin tube can inhibit the degradation rate of ProGRP, extend the holding time of ProGRP samples.
To achieve the above object, the present invention can take following technical proposals：
Protection of the present invention and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma, including test tube, in institute
It states test tube opening and is provided with seal rubber plug and the outer cap of plastics, be pre-charged with by casein, lauryl sodium sulfate in the test tube
The protective agent being formulated with Aprotinin.
The content of casein is 1 ~ 5% in the protective agent, and the content of lauryl sodium sulfate is 1 ~ 5%, and Aprotinin contains
Amount is 0.1 ~ 1mg/L.
The ingredient ratio for preparing casein, lauryl sodium sulfate and Aprotinin in the protective agent completed is 5:10:Effect when 1
Most preferably.
When actual production, the material of the test tube is poly- terephthaldehyde's carboxylic ester, and the material of the seal rubber plug is butyl
Rubber.
The negative pressure of vacuum of the test tube is 5ml or 10ml.
The present invention in use, acquire blood, and it is uniformly mixed to be turned upside down, then according to routine according to a conventional method
After operating method carries out the centrifugal treating of serum or blood plasma, in 2 ~ 8 DEG C of preservations.
The advantage of the invention is that：Due to being pre-charged with protective agent in heparin tube, the guarantor of ProGRP samples is substantially prolonged
It deposits the time, on the one hand facilitates clinical operation application, repetition measurement can also be carried out when suspecting individual pattern detection results abnormities, drop
The low probability of testing result false negative, improves the accuracy and clinical value of the item detection result.
Since ProGRP is easily by the proteasome degradation in sample, so as to cause the unstable of Sample preservation.The present invention uses
Lauryl sodium sulfate（SDS）（A kind of anionic surfactant）Coordinate with certain density SDS, protein can be destroyed
In ionic bond and the non-covalent bonds such as hydrogen bond, or even change the conformation of protein, ProGRP dropped to play blocks protein enzyme
The effect of solution.When pH value of solution casein isoelectric point (4.8) below when, the positively charged casein of molecular surface can be made by electrostatic
Casein/SDS compounds are combined into with electronegative SDS hydrophilic groups, which can occur mutually to hand over by protein molecular
Connection acts on, to degradation of the blocks protein enzyme to ProGRP.
Description of the drawings
Fig. 1 is the structural schematic diagram of heparin tube of the present invention.
Specific implementation mode
As shown in Figure 1, the heparin tube of the present invention protected and stablize gastrin-releasing peptide precursor in serum or blood plasma,
Including test tube 1,1 opening of test tube is provided with cap 3 outside seal rubber plug 2 and plastics, to extend the preservation of serum or plasma sample
Time is pre-charged with the protective agent 4 being formulated by casein, lauryl sodium sulfate and Aprotinin in test tube 1 of the invention.
The content of casein is 1 ~ 5% in protective agent of the present invention（w/v）, the content of lauryl sodium sulfate is 1 ~ 5%（w/
v）, the content of Aprotinin is 0.1 ~ 1mg/L；When practical preparation, casein, lauryl sodium sulfate and Aprotinin in protective agent 4
Ingredient ratio be 5:10:Best results when 1.
Poly- terephthaldehyde's carboxylic ester material that hydrophobic property can be used in the test tube 1 of the present invention is made, and seal rubber plug can be adopted
It is made of butyl rubber.
The negative pressure of vacuum of test tube of the present invention may be designed as 5ml or 10ml, to meet its testing requirements.
The production method of 1 heparin tube of the present invention of embodiment
The first step allocates the ingredient of protective agent 4 in proportion（In terms of 1L）：
Purified water 1000mL is measured, NaH is sequentially added2PO4·2H2O 0.59g、Na2HPO4·12H2O 5.8g、NaCl 9g、
Casein 10g, lauryl sodium sulfate 20g, Aprotinin 2g, ProClin300 1mL, stirring is until mixed solution clarification is saturating
It is bright.Then it carries out frozen dried using vacuum freeze drier and obtains lyophilized cake, reuse homogenizer processing lyophilized cake and obtain
Even powder, as protective agent 4.
Second step cleans 1 inner wall of test tube, by deployed 4 injecting tube 1 of protective agent under the sterile working environment of super-clean bench
Bottom, addition are the 1 ~ 5% of heparin tube blood volume（w/v）；
Third walks, and carries out vacuumize process according to the metering of heparin tube, then assembles cap 3 outside seal rubber plug 2 and plastics, at
Product heparin tube structure is as shown in Figure 1.
The 2 Sample preservation time of embodiment compares
Blood sample treatments are carried out at the same time using the heparin tube and conventional common tube heparin tube of the present invention, examine 10 samples altogether.It takes out
It turns upside down after blood 10 times, is placed in 37 DEG C of incubators and places 30min, 10min is centrifuged under the rotating speed of 4000 turns/min after taking-up；
Centrifugation is placed on 2 ~ 8 DEG C of preservations.Respectively at 0h, 3h, 1 day, 3 days, 5 days, 7 days, 14 days time points, certain commercially available company is used
Gastrin-releasing peptide precursor detection kit is detected sample, sample of the two kinds of heparin tubes of examination under 2 ~ 8 DEG C of preservation conditions
This stability the results are shown in Table 1 and table 2.
The heparin tube Sample preservation time of the present invention under the conditions of 12 ~ 8 DEG C of table
The conventional common tube heparin tube Sample preservation time under the conditions of 22 ~ 8 DEG C of table
There is stomach in protection and stable serum or blood plasma using of the present invention it can be seen from the experimental data of Tables 1 and 2
Secretin discharges the heparin tube of peptide precursor, and ProGRP samples can stablize preservation 7 days at 2 ~ 8 DEG C, and the range of decrease is less than 10%.And it uses normal
The common tube heparin tube of rule, after ProGRP samples preserve 1 day at 2 ~ 8 DEG C, the range of decrease has reached 20%, and with the extension of time
The range of decrease is increasing.
Claims (5)
1. a kind of protection and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma, including test tube, in the test tube
Opening is provided with seal rubber plug and the outer cap of plastics, it is characterised in that：It is pre-charged in the test tube by casein, dodecyl sulphur
The protective agent that sour sodium and Aprotinin are formulated.
2. protection according to claim 1 and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma, special
Sign is：The content of casein is 1 ~ 5% in the protective agent, and the content of lauryl sodium sulfate is 1 ~ 5%, the content of Aprotinin
For 0.1 ~ 1mg/L.
3. protection according to claim 1 or 2 and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma,
It is characterized in that：The ingredient ratio of casein, lauryl sodium sulfate and Aprotinin is 5 in the protective agent:10:1.
4. protection according to claim 1 or 2 and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma,
It is characterized in that：The material of the test tube is poly- terephthaldehyde's carboxylic ester, and the material of the seal rubber plug is butyl rubber.
5. protection according to claim 1 or 2 and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma,
It is characterized in that：The negative pressure of vacuum of the test tube is 5ml or 10ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810088563.9A CN108279307B (en) | 2018-01-30 | 2018-01-30 | Blood collection tube for protecting and stabilizing gastrin releasing peptide precursor in serum or plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810088563.9A CN108279307B (en) | 2018-01-30 | 2018-01-30 | Blood collection tube for protecting and stabilizing gastrin releasing peptide precursor in serum or plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108279307A true CN108279307A (en) | 2018-07-13 |
| CN108279307B CN108279307B (en) | 2021-01-26 |
Family
ID=62807028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810088563.9A Active CN108279307B (en) | 2018-01-30 | 2018-01-30 | Blood collection tube for protecting and stabilizing gastrin releasing peptide precursor in serum or plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108279307B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109342728A (en) * | 2018-10-18 | 2019-02-15 | 郑州标源生物科技有限公司 | A kind of quality-control product being applicable in tumor markers Pro-GRP quantitative detection |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770385A (en) * | 1992-06-12 | 1998-06-23 | Tonen Corporation | Antibodies to human gastrin-releasing peptide precursor and use thereof |
| CN102084249A (en) * | 2007-10-26 | 2011-06-01 | 株式会社先端生命科学研究所 | Antibody directed against pro-gastrin releasing peptide, and use thereof |
| CN102101975A (en) * | 2009-12-16 | 2011-06-22 | 罗门哈斯公司 | Low odor compositions and low odor coating compositions |
| CN105158455A (en) * | 2015-09-17 | 2015-12-16 | 深圳市钠科生物有限公司 | Biological sample collecting method, device and system for improving sample detection precision and accuracy, biological sample stabilizing reagent and application |
| US20170089889A1 (en) * | 2006-12-11 | 2017-03-30 | Abbott Laboratories | Immunoassay method for pro-gastrin-releasing peptide |
| CN106701743A (en) * | 2016-12-26 | 2017-05-24 | 广州和实生物技术有限公司 | Blood collection tube for protecting and stabilizing free DNA |
-
2018
- 2018-01-30 CN CN201810088563.9A patent/CN108279307B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770385A (en) * | 1992-06-12 | 1998-06-23 | Tonen Corporation | Antibodies to human gastrin-releasing peptide precursor and use thereof |
| US20170089889A1 (en) * | 2006-12-11 | 2017-03-30 | Abbott Laboratories | Immunoassay method for pro-gastrin-releasing peptide |
| CN102084249A (en) * | 2007-10-26 | 2011-06-01 | 株式会社先端生命科学研究所 | Antibody directed against pro-gastrin releasing peptide, and use thereof |
| CN102101975A (en) * | 2009-12-16 | 2011-06-22 | 罗门哈斯公司 | Low odor compositions and low odor coating compositions |
| CN105158455A (en) * | 2015-09-17 | 2015-12-16 | 深圳市钠科生物有限公司 | Biological sample collecting method, device and system for improving sample detection precision and accuracy, biological sample stabilizing reagent and application |
| CN106701743A (en) * | 2016-12-26 | 2017-05-24 | 广州和实生物技术有限公司 | Blood collection tube for protecting and stabilizing free DNA |
Non-Patent Citations (1)
| Title |
|---|
| 江承平 等: "抑肽酶对凝血酶所致星形胶质细胞损伤的保护作用", 《中华临床医师杂志（电子版）》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109342728A (en) * | 2018-10-18 | 2019-02-15 | 郑州标源生物科技有限公司 | A kind of quality-control product being applicable in tumor markers Pro-GRP quantitative detection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108279307B (en) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110095608A (en) | Tumour excretion body nano fluorescent sensor based on Magnetic Isolation and DNA self assembly | |
| CN104655843A (en) | Gastric cancer detecting method, reagent and gastric cancer detecting kit | |
| CN104650234B (en) | Anti- AKR1B10 protein monoclonal antibodies and its application | |
| Gerfo et al. | Tumor associated antigen with pulmonary neoplasms | |
| Goldstein et al. | Usefulness of tumor markers in serum and bronchoalveolar lavage of patients undergoing fiberoptic bronchoscopy | |
| CN110646624A (en) | ELISA reagent diagnosis kit of matrin 2 and use method thereof | |
| Acién et al. | Epithelial ovarian cancers and endometriosis | |
| CN108872438A (en) | Lung cancer marker GK5 quick detection kit in a kind of excretion body | |
| CN106950374A (en) | Application of the albumen of Glypican 1 in diagnosis of pancreatic cancer, the detection method of positive excretion bulk concentration and application thereof | |
| Pan et al. | Assessment of cancer cell migration using a viscosity-sensitive fluorescent probe | |
| CN108279307A (en) | Protection and the heparin tube for stablizing gastrin-releasing peptide precursor in serum or blood plasma | |
| CN107132323A (en) | Piperacillin induction hemolysis test kit and preparation method thereof | |
| Sica et al. | PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens | |
| ASPLUND | A Quantitative Determination of the Content of Contractive Substances in Human Sperm and their Significance for the Motility and Vitality of the Spermatozoa. | |
| JP2004170434A (en) | Method of detecting gynecologic cancer | |
| Tarbet et al. | Histochemical investigation of the spherule of Coccidioides immitis in relation to host reaction | |
| CN103884549A (en) | Sputum cell treatment liquid and application thereof | |
| Sherlock et al. | The role of early diagnosis in controlling large bowel cancer. An overview | |
| WO2023104059A1 (en) | Circulating tumor cell detection material, detector and detection method | |
| CN113899904B (en) | Method for detecting extracellular vesicle membrane protein for predicting curative effect of gastric cancer immunotherapy | |
| CN207007817U (en) | Piperacillin induces hemolysis test kit | |
| CN109239332A (en) | A kind of kit of auxiliary detection sub-health population cancer base antigen | |
| Li et al. | Successful treatment of Talaromyces marneffei infection in a kidney transplant recipient with voriconazole followed by itraconazole for the first time | |
| Sadoughi et al. | Prognostic value of cell surface antigens using immunoperoxidase methods in bladder carcinoma | |
| CN106896016A (en) | The rapid extracting method of acrosin and its flow cytometer detection method of activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |